Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Multiple-dose, Two-arm, One-sequence • Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration Telmisartan/S-amlodipine and Rosuvastatin in Healthy Volunteers

Next Previous
Trial Profile

A Randomized, Open-label, Multiple-dose, Two-arm, One-sequence • Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration Telmisartan/S-amlodipine and Rosuvastatin in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levamlodipine/telmisartan (Primary) ; Rosuvastatin
  • Indications Hypertension
  • Focus Pharmacokinetics
  • Acronyms CKD-346 DDI P1
  • Sponsors Chong Kun Dang

Most Recent Events

  • 18 Jun 2014 New source identified and integrated (Clinical Research Information Service (CriS) - Republic of Korea - KCT0001086 ).
  • 16 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 05 Feb 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top